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There are about 7000 new cases of epidermoid carcinoma of the
oropharynx per year making up 95% of malignant oropharyngeal
tumours. The incidence has been steadily rising and France has the
highest incidence of this cancer in the world. 
The vast majority of oropharyngeal cancers are squamous cell
carcinomas. This document does not consider other rare
neoplasms (e.g. mucosal melanoma, plasmacytoma, soft-tissue
sarcoma or minor salivary gland tumours) occasionally found in
the head and neck. The management of patients with oropharyn-
geal cancer requires a multidisciplinary team of individuals with
expertise in all aspects of the special care needs of these patients. 
These guidelines were validated in June 1999 by the working
group. An update is planned for 2001/2 
INITIAL ASSESSMENT 
The initial ‘work-up’ of a patient with oropharyngeal cancer
involves clinical examination coupled with imaging studies. 
The clinical examination must assess the patient’s performance
status and any signs suggestive of probable extensive disease (e.g.
trismus, reduced lingual protraction, earache) (standard). The
history taking must cover alcohol and tobacco use and quality of
life issues (standard). A general anaesthetic may be necessary for
the assessment of locoregional extension and for tumours at 
the base of the tongue. The tumour must be measured. The
morphology of the tumour (e.g. whether it is exophytic, infiltrating
or ulcerative), should be noted along with any infiltration of adja-
cent structures (e.g. the mandible) or of muscles (masticators,
muscles at the base of the tongue). 
Initial assessment includes a biopsy for histological confirma-
tion. Clinical examination of cervical lymph node areas must note
the presence of nodes, their sites, dimensions, mobility and
number (standard). 
Standard investigations are a chest X-ray (CXR) to look for
synchronous bronchial tumours and orthopantomography to detect
any dental defects that should be corrected prior to treatment. 
Optional examinations include: 
l oesophagoscopy (to look for synchronous tumours) 
l CT scan or MRI of the head and neck (in case of suspicion of
deep muscle and/or bone involvement) 
l cervical ultrasonography (to evaluate the extension of cervical
nodes in obese patients with no palpable lymphadenopathy) 
l panendoscopy (if there is a history of prolonged alcohol and
tobacco use) 
l bronchoscopy (if there is suspicion of a second cancer on
CXR). 
A search for metastases is only indicated if there are clinical symp-
toms and signs suggestive of disease spread. 
CLASSIFICATION 
The TNM classification of the International Union Against Cancer
(UICC) is the one most commonly used. 
PROGNOSTIC FACTORS 
Prognosis is related to: 
l the degree of locoregional extent as assessed clinically (the
size and mobility of the primary tumour, extension to muscle
or bone, the presence of lymph nodes and whether they are
fixed) 
l histological factors linked to the tumour (tumour grade, thick-
ness, quality of the surgical margins) 
l histological factors linked to lymph nodes (invasion, capsular
rupture, nodal site and a number of involved nodes). 
The role of tumour markers as prognostic factors is currently being
evaluated. Stage at diagnosis is the factor most predictive of
survival. In general, the survival rate of patients with locally
advanced disease (stage III or IV) is less than half that of patients
with early stage disease (stage I or II). Distant metastases are
uncommon at presentation. 
TREATMENT MODALITIES 
The therapeutic techniques include surgery, radiotherapy,
brachytherapy and combined radiotherapy and chemotherapy. As
there are no randomized trials to guide management in oropharyn-
geal cancer, all therapeutic decisions should be made by a multi-
disciplinary team, in order to define the treatment best suited to
each individual case. 
Tumours of the base of the tongue 
There is no difference between external radiotherapy, radiotherapy
plus brachytherapy or surgery with or without radiotherapy for
local control of T1–T3 disease that is in the order of 70–90%
(level of evidence C). For T4 tumours, the rate of local control is
considerably lower. There may be an advantage in favour of
combination surgery and radiotherapy. 
Tumours of the tonsillar fossae and anterior pillars 
For limited stage disease (T1–T2), external radiotherapy, radio-
therapy plus brachytherapy and surgery followed by postoperative
radiotherapy give equivalent results in terms of local control (90%
for T1 and 75–80% for T2 tumours) (level of evidence C). For T3
tumours, the combination of radiotherapy and brachytherapy is
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evidence C). Surgical series do not detail results in terms of T
stage. The results of surgery alone are not directly comparable to
those of radiotherapy/brachytherapy but are similar. For T4
tumours, no comparison between different treatments is possible.
The failure rate is greater than that for T3 tumours (level of
evidence C). 
Tumours of the soft palate and uvula 
The three treatment modalities (surgery, radiotherapy, radio-
therapy and brachytherapy) give equivalent rates of local control
for limited stage disease (70–100% for T1 and 60% for T2
tumours) (level of evidence C). There is no consensus as to the
best modality for stage T3/T4 disease. 
Lymph node areas 
The results of treatment of cervical lymph node areas with surgery
or radiotherapy are equivalent for N0 and N1 disease with a high
rates of control (96–100% for N0, 90–93% for N1 disease). If
nodes are involved, postoperative radiotherapy seems to reduce
the frequency of recurrence (level of evidence C). There is no
consensus as to the relative efficacy of radiotherapy and surgery
for T3 disease, but as the rate of local recurrence tumours is high
(in the order of 30%), if either method is used alone. They are
usually combined. This applies to the treatment of lymph node
areas for all the cancers of the upper aerodigestive tract. 
CHEMOTHERAPY 
Neoadjuvant and adjuvant chemotherapy do not improve locore-
gional control or survival in oropharyngeal cancer (level of
evidence A). Combined radiochemotherapy, either alone or in
addition to surgery, can improve both local control and survival in
extensive but potentially curable lesions of the oropharnynx (T3,
T4a, N0 to N3) when compared to surgery and radiotherapy (level
of evidence A). The role of radiochemotherapy as compared to
radiotherapy alone (particularly with hyperfractionation), remains
to be confirmed in clinical trials. 
Neoadjuvant or adjuvant chemotherapy should not be offered to
patients with cancer of the oropharynx who are potentially treat-
able by locoregional methods (level of evidence A). Combination
radiochemotherapy given postoperatively for cancers at risk of
local recurrence, or given as sole treatment for extensive cancers,
are options. If possible, these patients should be included in
clinical trials. 
TREATMENT STRATEGY 
T1, N0, M0 tumours of the oropharnyx 
There is no standard. Surgery and radiotherapy have equivalent
efficacy (level of evidence B). Simple surgical excision by the oral
route, brachytherapy or external radiotherapy are therapeutic
options (Figure 1). 
The choice of treatment depends on the likelihood of functional
and cosmetic sequelae, on social considerations and the views of the
patient. Surgery is preferable for lateral lesions if it can be done via
the oral route, as this will result in very few functional sequelae and
in young patients lessens the risk of second malignancies. When
the margins of surgical excision are narrow (less than 5 mm) or
invaded, additional radiotherapy is recommended (level of
evidence B). 
Elective treatment of lymph node areas is optional. If the
primary tumour is treated surgically, this should consist of an
exploration of the supra-omohyoid area, followed by a selective
neck dissection if one or more nodes are positive, preserving the
sternocleidomastoid muscle, jugular vein and spinal accessory
nerve. For lateral tumours, cervical irradiation can be limited to
the ipsilateral cervical zones without compromising local control
(level of evidence B). Treatment of local recurrence gives the
same results in terms of cervical control and survival (level of
evidence B). The choice of treatment of lymph node areas should
be made according to the preference of the patient and the multi-
disciplinary team. 
T1, N1, M0/T2, N0–N1, M0 tumours 
There is no standard. Surgical excision plus exploration of the
supra-omohyoid nodes (with clearance if the nodes are positive),
external radiotherapy to the tumour and the cervical nodes or
conventional radiotherapy plus brachytherapy are the therapeutic
options. The choice of treatment is individualized and dependent
on performance status, age and patient preference. 
The therapeutic options for the primary tumour include surgery
and external radiotherapy or brachytherapy plus external radio-
therapy, the efficacy of which are equivalent for this type of lesion
with a local control rate in the order of 90% (level of evidence B).
Surgery is preferable for lateral tumours and infiltrating or ulcera-
tive tumours which are likely to respond less favourably to radio-
therapy. Additional radiotherapy is necessary when the surgical
margins are narrow (less than 5 mm), or involved, to reduce the
risk of local recurrence (level of evidence B). Radiotherapy alone,
or radiotherapy plus brachytherapy, is preferable for those in
whom surgery is likely to produce a considerable functional
deficit. 
Elective treatment of uninvolved lymph node areas (N0) can be
considered for larger tumours (T2) in order to reduce the risk of
cervical relapse (level of evidence B). For lateral tumours, cervical
irradiation can be limited to ipsilateral cervical nodes (level of
evidence B). In patients who have had surgery, the presence of
unequivocal nodal disease, histological involvement of several
nodes or capsular rupture, are indications for postoperative irradia-
tion to reduce the risk of cervical recurrence (level of evidence B). 
T3, N0–N2 M0/T1–T2, N2, tumours 
There is no standard. The options are: surgical excision plus neck
dissection, radical resection followed by postoperative radio-
therapy, postoperative radiochemotherapy, external radiotherapy
plus brachytherapy, hyperfractionated radiotherapy or combined
radiochemotherapy. External radiotherapy should be considered if
the tumour is totally exophytic. All patients should be considered
for entry into controlled trials. 
The macroscopic appearance of the tumour (exophytic or
ulcero-infiltrating) can dictate the choice of treatment. Surgery 
is preferable for infiltrating lesions (level of evidence C). Radio-
therapy associated with brachytherapy gives equivalent results to
surgery. This is preferable to combination surgery/radiotherapy in
exophytic disease or in those cases with minimal infiltration when
the predicted functional outcome following surgery is important
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tive radiotherapy is more effective than radiotherapy alone, or
radiotherapy associated with brachytherapy for extensive ulcero-
infiltrative tumours (level of evidence B). The addition of
chemotherapy either combined with radiotherapy or given postop-
eratively, significantly increases local control and survival (level
of evidence A), but also increases morbidity. At present, there is no
consensus as to the role of hyperfractionated radiotherapy. 
The are various surgical methods (e.g. differences in route of
approach, techniques of reconstruction, etc), but there is little
difference with respect to functional result. There is no justifica-
tion for the routine resection of the mandible, except when there is
obvious invasion of bone. Postoperative specialist rehabilitation
that includes functional aids for every-day living must be offered
to patients. 
In view of the frequency of microscopic nodal involvement,
cervical lymph node areas should be treated routinely. Cervical
clearance is always preferable to radical clearance because of the
difference in functional outcome and because the rate of local
control is the same (level of evidence B). For patients with N1
disease, neck dissection or adenectomy is indicated if nodes persist
following potentially curable external radiotherapy. This addi-
tional surgery is generally recommended if the nodes were origi-
nally larger than 3 cm. 
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Figure 1 Treatment of limited-stage carcinoma of the oropharynx 
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Figure 2 Postoperative treatment of limited-stage disease T4, N0–N2, M0/all N3 tumours 
There is no standard. Treatment and prognosis depends on the
operability of the primary tumour and/or lymph nodes. 
For stage T4, N0–N2, M0/all N3 disease with resectable tumour
and nodes the options are: 
l surgery plus postoperative radiotherapy 
l surgery plus concomitant radiochemotherapy 
l concomitant radiochemotherapy alone. 
Patients should be included in therapeutic trials whenever
possible. 
For resectable tumours, the combination of surgery and radio-
therapy is the most efficacious treatment with a control rate 
in the order of 60–70% (level of evidence B). Postoperative
radiochemotherapy or radiochemotherapy alone are options, if
possible within controlled trials. The surgical methods utilised (i.e.
the route of approach and methods of reconstruction) will depend
on the expertise and experience of the surgeon, who must be
familiar with the diverse techniques used in these complex situa-
tions. In those patients refusing surgery, radiochemotherapy 
and hyperfractionated radiotherapy given within a study can be
considered. 
For non-resectable T4, N0–N2, M0/all N3 tumours, external
radiotherapy and experimental treatment within controlled
trials are therapeutic options. Combined radiochemotherapy, with
radiotherapy protocols evaluating different schema of hyperfrac-
tionation, brachytherapy, new types of ionizing radiation and
hyperthermia are being evaluated. The primary aim of treatment is
palliation. External radiotherapy will occasionally allow subse-
quent surgery of curative intent. Patients should be included in
controlled trials whenever possible. 
FOLLOW-UP 
Clinical examination, naso-fibroscopy of the upper aerodigestive
tract, and clinical assessment of nodal areas are routine investiga-
tions. An annual chest X-ray is justified in those patients at risk of
a bronchial cancer. Additional investigations are undertaken
according to symptomatology. In the case of suspicion of loco-
regional recurrence or distant spread, the evaluation should be
the same as the initial assessment. 
The recommended frequency of follow-up is: clinical examina-
tion every 3 months for the first 2 years, then every 6 months for
the following 3 years, then annually. 
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Figure 4 Assessment of advanced-stage disease 
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Figure 5 Treatment of advanced-stage disease 